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Supplemental Methods  
Implantation of telemetry, BP measurement and metabolic cages 
BP telemetry devices, TA11PA-C40 (Data Science International, St Paul, MN, USA), 
were implanted as previously described (1) in the abdominal aorta of the rats. In short, 
following midline abdominal incision, the aorta was prepared and punctured just above 
the bifurcation using a 23-gauche needle for insertion of the telemetry catheter. After 
sealing (Vetbond 3M, Aichele Medico, Aesch, Switzerland) and control of the catheter 
placement, the device battery was attached to the left lateral abdominal wall and the skin 
closed. The data (systolic and diastolic BP) were transmitted to a receiver and collected 
for 10s, every 15min (Fig. S2).  
After 3w of recovery, the animals were transferred to metabolic cages for approximately 
30h before mating and at days 3 to 4 (week 1), 10 to 11 (week 2), and 16 to 17 (week 3) 
of pregnancy. A second cohort of non-pregnant rats was placed in metabolic cage at the 
same time points. Urine was collected and food/water intake was monitored. Telemetric 
BP recordings were obtained for 3d before mating and throughout pregnancy when the 
animals were returned to their original cage.  
 
Urine analysis 
Urinary creatinine and Na+ excretion were determined in our central hospital 
laboratories using validated routine clinical methods. Na+ balance was calculated as the 
ratio of Na+ intake vs. urinary Na+ excretion, A high ratio thus indicates a Na+ retention. 
  
RNA extraction and TaqMan PCR analysis of components of the RAS in the renal cortex 
and medulla 
Independent frozen kidney specimens (n=3 animals) were pulverized in liquid nitrogen 
and homogenized by ultrasonic homogenizer (20s) with RNA being extracted using the 
SV total RNA isolation kit or by the Trizol method. Using 2ug of RNA, reverse 
transcription using the Super Script III RT-PCR system was completed (Invitrogen, 
USA). Homology-based quantitative TaqMan PCR was performed with Roche 
Universal Probe Library primers and probes for angiotensinogen, angiotensin 
converting enzyme, renin, angiotensin receptor 1a and 1b, and the ENaC subunits α, β 
and γ to identify and quantify the respective transcripts. Negative controls for the RT 
and the PCR reagents were assessed. The geometric mean of β-actin, HPRT1 and Hmbs 
served as endogenous controls (Supplemental Table S2). Each measurement was 
repeated in triplicates. 
 
Sample preparation for Western blot analysis  
Independent plasma membrane fractions (n=3 animals) were prepared of cortical and 
medullary renal specimens. The frozen kidney specimens were pulverized in liquid 
nitrogen and homogenized by ultrasonic homogenizer (20s) in ice-cold homogenisation 
buffer containing 250mmol/L sucrose, 10mmol/L triethanolamine, 10mmol/L Na+-
pyrophosphate, 1mmol/L Na+-orthovanadate, 100mmol/L Na+-fluoride, 1.3mg/10μl 
DMSO of N-ethilaleimide and one tablet of complete protease inhibitor cocktail per 2ml 
(Roche, Grenzach-Wyhlen, Germany). The homogenate was centrifuged at 1,000g and 
4°C for 5min and the supernatant was further centrifuged at 20,000g and 4°C for 60min 
to obtain a fraction enriched for plasma membranes. The pellet was resuspended in 
sucrose buffer containing phosphatase and protease inhibitors. 
 All protein concentrations from kidney cortex and medulla homogenates were 
determined using a colorimetric protein assay based on the biuret reaction (Pierce, BCA 
Protein Assay Kit, Thermo Scientific, Switzerland), using an albumin standard to 
establish a linear calibration curve. 
 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting  
The protein separation was performed by the SDS-Page method in an electrophoresis 
chamber (Biorad, California, USA) using an electrophoresis buffer consisting of 1% 
SDS, 192mmol/L glycine and 25mmol/L Tris at pH 8.3. The samples were dissolved in 
Laemmli buffer (3% SDS, 10% glycerol, 5% mercaptoethanol, 1% bromophenol blue, 
95mmol/L Tris [pH 6.8]), denatured for 5min at 95°C, and loaded on 10% or 12% 
acrylamide gels. The molecular weight was determined with Page Ruler Plus prestained 
protein ladder (Thermo Fisher Scientific Inc., USA). The protein was transferred from 
the gel to a nitrocellulose membrane (Brunschwig, The Netherlands) with a tank-
sandwich Western blotting system under permanent cooling conditions. Equal loading 
and electrophoretic transfer quality of the proteins onto nitrocellulose membranes were 
verified using 0.1% Ponceau red staining. Membranes were blocked with 5% skim milk 
for 60min and then incubated overnight at 4°C with primary antibodies. Thereafter, 
membranes were extensively washed with 0.5% Tween/TBS solution and incubated 
with secondary antibodies for 2h. Immunoreactive bands were detected using an 
enhanced chemiluminescence kit (Amersham ECL Select Western Blotting Detection 
Reagent, GE Healthcare, UK) followed by subsequent acquisition using Syngene G:Box 
Chemi XX6 software (Cambridge, UK). Band intensity was evaluated using Image J 
and normalized to β-actin abundance with control values set as 100%. Each 
measurement was repeated in triplicates. 
For Western blot previously well-characterized primary antibodies were used: The non-
commercial polyclonal, anti-rabbit antibodies against full length α-subunits of ENaC 
(1:500 (2)), against a synthetic peptide mapping to the N-terminal amino acids 46-68 
(StressMarq Biosciences Inc., Victoria BC CANADA, catalogue # SPC-403; 1:500), 
against β-subunits of ENaC (1:500 (2)), against γ-subunits of ENaC (1:500 (2)), and 
against β-actin (Santa Cruz Biotechnology, Inc., USA; 1:2000). As secondary antibody 
was used HRP-conjugated affinity purified donkey anti-rabbit IgG (Jackson 
ImmunoResearch Laboratory Europe Ltd., UK; 1:5,000). 
 
 Table S1. Impact of salt intake on body weight, food and water consumption in 
non-pregnant (n=3-5) and pregnant (n=4) rats. 





NS HS LS 
HS/LS 
HS LS 
Weight gain (day 20)  
[% of initial body weight] 14.0± 4.0 14.7± 1.3  8.9± 7.6                                  10.8± 6.6 
Water intake  
[ml/100g BW/d] 12.0± 5.2  26.5± 1.5* 15.9±12.5 26.5±1.8*  10.4± 9.8§ 
Food intake  
[g/100g BW/d] 11.5± 0.6 14.0± 1.1 12.6± 0.9 13.2±1.7 11.9± 1.2 
            
   Pregnant   
 
    
  
  
NS HS LS 
HS/LS 
HS LS 
Weight gain (day 20)  
[% of initial body weight] 45.7±11.8 30.1±11.7* 18.5± 9.3***                                  28.9± 6.4*
Weight gain (day 20) 
[% of initial body weight/fetus] 2.0± 0.9  1.4±1.4   0.8± 0.9*   1.2± 0.5 
Water intake  
[ml/100g BW/d] 15.9± 9.4 29.6± 3.7** 22.7± 5.2 32.0±5.4*** 19.6± 6.2§ 
Food intake 
[g/100g BW/d] 14.1± 2.8 12.0± 2.0 13.0± 0.8 12.7±1.4  10.2± 0.9** 
 
Results in mean ± SD  *P<0.05  **P<0.001  *** P< 0.0001 vs. NS 
    §P<0.05 between the switch of salt diet (HS to LS) 
 Table S2. Mean absolute expression levels of components of the RAS as assessed 
by TaqMan PCR (average Ct values). 
Gene Cortex Medulla 
Angiotensinogen 30 29 
ACE 28 27 
Renin 25 26 
Angiotensin receptor 
subtype 1a 29 28 
Angiotensin receptor 
subtype 1b 32 32 
ENaC-α 26 28 
ENaC-β 28 28 
ENaC-γ 31 33 
 
 Table S3. Primers used in real-time PCR. 
Gene Accession number Primers Probe 
Amplicon size 
(nt) 
          
     
Angiotensinogen NM_134432.2 5'- GAT AAA GAA CCC GCC TCC TC -3’ 62 117 
  5'- GCA CCC AAA AGG GTA GAC AG -3’   
     
ACE NM_012544.1 5'- CCA ACA TCA CGG AGG AGA AT -3’ 1 69 
  5'- CCT CTG CAA ACT CCT GGT TG -3’   
     
Renin NM_012642.4 5'- TGT AGC TTC AGT CTC CCG ACA -3’  76 66 
  5'- CGA GGG CAT TTT CTT GAG C -3’   
     
AGTR1a NM_030985.4 5'- CAC CCG ATC ACC GAT CAC -3’  53 110 
  5'- CAG CCA TTT TAT ACC AAT CTC TCA -3’   
     
AGTR1b NM_031009.2 5'- GAC ACA CAC AGC CTT TCC AG -3’  49 113 
  5'- GCT CTC TGA CAC TAT TTA AAA TGC AC -3’   
     
ENaC-α  NM_031548.2 5'- CCA AGG GAG TTG AGT TCT GTG -3’ 128 75 
  5'- AGG CGC CCT GCA GTT TAT -3’   
     
ENaC-β  NM_012648.1 5'- GGC ATG ACA GAG AAG GCA CT -3’  95 77 
  5'- TGA CCA ATG TCC AGG ATC AA -3’   
     
ENaC-γ NM_017046.1 5'- CTA CAC ATT TAA CAA CAA AGA AAA TGC -3’  73 94 
  5'- TTC GTT TAT GTA TAA GAT GAC TTG CAG -3’   
     
β-actin NM_031144.2 5'- CCC GCG AGT ACA ACC TTC T -3’  17 72 
  5'- CGT CAT CCA TGG CGA ACT -3’   
     
HPRT1 NM_012583.2 5'- GGT CCA TTC CTA TGA CTG TAG ATT TT -3’  22 126 
  5'- CAA TCA AGA CGT TCT TTC CAG TT -3’   
     
Hmbs NM_013168.2 5'- TCC CTG AAG GAT GTG CCT AC -3’  79 73 
  5'- AAG GGT TTT CCC GTT TGC -3’   
     
          
 
 Table S4. Numerical data of figures. 
To figure 1A 
Na+ intake [g/d] 








































































To figure 1B 
Urinary Na+ excretion [mmol/mmol creatinine] 
  Before Week 1 Week 2 Week 3 
Nonpregnant NS  15±  2  15±  3  13±  3  13±  2 
 HS  19±  4 237± 45 279± 79 255±131 
 LS  18±  4   3±  1   1±  0   3±  1 
 HS/LS  22±  4 220± 48 285± 19   5±  5 
Pregnant NS  24±  7  15±  2  13±  7  11±  3 
 HS  19±  6 303± 24 174± 79 282± 67 
 LS  18±  2   4±  2   1±  1   0±  0 
 HS/LS  17±  5 314± 36 199± 26   2±  2 
 
To figure 1C 
Na+ intake/urinary Na+ excretion [(mg Na+)/(mmol Na+/mmol creatinine)] 
  Before Week 1 Week 2 Week 3 
Nonpregnant NS 10.3± 1.6 11.5± 1.6  9.8± 0.9 10.8± 2.4 
 HS 10.9± 2.8 14.3± 6.1 13.5± 5.2 13.6± 0.3 
 LS  8.7± 1.2  1.6± 0.7  2.6± 0.8  1.4± 0.3 
 HS/LS  9.8± 2.8 17.2± 6.4 13.2± 5.2  4.0± 3.3 
Pregnant NS  7.9± 3.4 15.0± 5.3 16.6± 7.9 15.7± 4.6 
 HS  7.4± 2.5 11.3± 1.5 14.9± 4.0 10.4± 1.4 
 LS  7.5± 0.7  1.6± 1.0  4.2± 2.2 38.6±31.9 
 HS/LS 10.3± 3.0 11.2± 1.4 13.9± 3.5  2.9± 2.4 
 
 To figures 2A-D 
Systolic blood pressure [% of baseline] 
 Day NS HS LS HS/LS 
Nonpregnant -2 100± 3 100± 3 101± 4 100± 3 
 -1 100± 8 100± 3  99± 5 100± 3 
 01 102± 6 101± 1 103± 5 101± 1 
 02 103± 6 104± 3 102± 3 104± 3 
 05 103± 7 108± 3 102±10 108± 3 
 06 104± 4 107± 5 102± 7 107± 5 
 07 103± 4 108± 6 101± 7 108± 6 
 08 103± 5 107± 6  98± 5 107± 6 
 09 100± 4 106± 3 100± 6 106± 3 
 12 103± 3 104±11 102± 8 104±11 
 13  99± 2 103± 6 105± 6 103± 6 
 14 101± 2 100± 7 102± 4 103± 6 
 15 102± 1 107± 6 100± 4  92± 6 
 18 102± 2 106± 1 104± 8  91± 7 
 19  99± 2 106± 6 102± 6  92± 5 
Pregnant -2 100± 3 100± 4 101±10 100± 4 
 -1 100± 2 100± 7 100±12 100± 7 
 01 101± 6 98±10 101±12  98±10 
 02 102± 5 100±10 100± 8 100±10 
 05 103± 4 100± 6 106± 8 100± 9 
 06 103± 3  99± 7 104± 7  99± 7 
 07 103± 2 100± 9 104± 4 100± 9 
 08 103± 4  95±12 103± 7  95±12 
 09 102± 8  95± 8 103± 8  95± 8 
 12 102± 4  96± 7 104±10  96± 7 
 13 103± 7  99± 3 101± 7  99± 3 
 14 104± 6  97± 7 100± 5  97± 7 
 15 103± 5  96± 9 103± 6  92± 4 
 18 101± 4  89± 8  97±11  93± 6 
 19  99± 5  84±11  90± 5  85± 5 
 
To figures 3A-B 
Change of normalized AUC of systolic blood pressure [% of baseline] 
  Before Week 1+2 Week 3 
Nonpregnant NS 0.0±0.0  2.6±2.1  1.5±5.6 
 HS 0.0±0.0  5.9±3.1  4.6±7.4 
 LS 0.0±0.0  1.2±1.9  1.9±1.7 
 HS/LS 0.0±0.0  4.9±2.6 -7.2±8.2 
     
Pregnant NS 0.0±0.0  2.5±4.8  1.8±4.1 
 HS 0.0±0.0 -2.1±4.4 -7.5±5.1 
 LS 0.0±0.0  2.6±3.1 -2.0±5.4 
 HS/LS 0.0±0.0 -1.6±2.5 -8.6±2.9 
 
To figures 4A-E 
 mRNA [relative expression] 
  NS HS LS HS/LS 
Angiotensinogen C-NP 1.0±0.2 1.3±0.1 0.5±0.1 0.7±0.2 
 C-P 1.0±0.2 1.0±0.3 1.1±0.2 0.7±0.1 
 M-
NP 
1.0±0.3 1.6±0.3 1.1±0.6 0.6±0.2 
 M-P 1.4±0.1 1.7±0.4 1.8±0.4 1.6±0.1 
ACE C-NP 1.0±0.2 0.8±0.1 0.8±0.1 0.5±0.2 
 C-P 0.2±0.1 0.5±0.2 0.5±0.1 0.7±0.1 
 M-
NP 
1.0±0.3 1.4±0.1 1.0±0.4 0.5±0.2 
 M-P 0.4±0.1 0.8±0.1 0.9±0.2 1.6±0.1 
Renin C-NP 1.0±0.5 0.3±0.1 1.0±0.5 0.5±0.1 
 C-P 1.0±0.5 0.3±0.1 2.0±0.3 1.1±0.4 
 M-
NP 
1.0±0.3 0.2±0.2 1.1±0.3 0.2±0.1 
 M-P 0.2±0.1 0.3±0.1 0.6±0.2 0.3±0.1 
AGTR1a C-NP 1.0±0.2 1.2±0.1 0.6±0.1 0.7±0.1 
 C-P 0.9±0.3 0.5±0.2 0.5±0.1 0.4±0.1 
 M-
NP 
1.0±0.2 1.8±0.2 0.7±0.1 1.0±0.1 
 M-P 0.8±0.2 1.2±0.2 0.4±0.1 0.5±0.1 
AGTR1b C-NP 1.0±0.2 0.9±0.1 0.8±0.2 1.0±0.2 
 C-P 0.9±0.5 0.5±0.2 0.6±0.2 0.4±0.1 
 M-
NP 
1.0±0.3 1.2±0.1 1.0±0.2 1.0±0.3 
 M-P 0.8±0.3 1.7±0.4 0.6±0.3 0.5±0.2 
 
To figure 5 
mRNA [relative expression] 
  NS HS LS HS/LS 
ENaC-α C-NP 1.0±0.1 1.1±0.1 0.8±0.1 0.9±0.1 
 C-P 1.0±0.3 0.7±0.0 0.6±0.2 0.5±0.1 
 M-NP 1.0±0.2 1.0±0.2 0.8±0.1 0.8±1.1 
 M-P 1.1±0.4 1.5±0.4 0.9±0.3 1.0±0.3 
ENaC-β C-NP 1.0±0.2 1.9±0.1 0.9±0.2 1.0±0.3 
 C-P 1.3±0.7 0.9±0.3 0.5±0.1 0.4±0.1 
 M-NP 1.0±0.3 0.9±0.2 0.7±0.2 0.7±0.3 
 M-P 0.7±0.1 0.7±0.1 0.4±0.2 0.4±0.1 
ENaC-γ C-NP 1.0±0.3 1.7±0.1 0.9±0.2 0.7±0.2 
 C-P 0.8±0.4 0.6±0.3 0.3±0.1 0.2±0.1 
 M-NP 1.0±0.3 0.8±0.4 0.7±0.2 0.8±0.3 
 M-P 0.7±0.3 1.0±0.1 0.6±0.4 0.4±0.1 
 
 To figures 6A-C 
Protein expression [% of β-actin] 
  NS HS LS HS/LS 
ENaC-α full C-NP   100± 30   70±10  100±10  280± 40 
 C-P   330± 90  210±10  190±10  510± 10 
 M-NP   110± 30  110±10  120±20  140± 60 
 M-P    40± 40  110±30  100±10  220± 50 
ENaC-α cleaved C-NP   100± 30  100±10  170±10  520± 30 
 C-P   420± 40  210±20  200±30  220± 10 
 M-NP   110±100  110±90  320±20  660± 30 
 M-P   700± 50  670±50 2100±30 1600± 50 
ENaC-β full C-NP   100± 40  110±10   70±20  100± 30 
 C-P   110± 20  100±20  120±20  190± 20 
 M-NP   100± 30  100±30  110±50  120±100 
 M-P   210± 50  360±10  450±40  520± 30 
ENaC-γ full C-NP   100± 10  110±20  120±30   80± 20 
 C-P    80± 40   80±20   50±50   70± 30 
 M-NP   110± 40   90±10  120±20  100± 20 
 M-P    70± 70  380±20  460±20  240± 60 
ENaC-γ cleaved C-NP   100± 10  100±10  170±20 7100± 10 
 C-P 10500± 10  350±80   80±10  170± 50 
 M-NP   110± 30   70±10  110±30   90± 50 
 M-P    40± 40   70±10   90±60   50± 50 
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Typical telemetry data obtained during the experimental periodFigure S2
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